Original Research

Published on 14 Jun 2024

Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States

in Drugs Outcomes Research and Policies

Ya-Ning Zhu
Meng Tang
Ke-Xin Sun
Bei Gao
Xian-Peng Shi
Peng Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1348688

907 views

Review

Published on 13 Jun 2024

Orphan drug policy analysis in China

in Drugs Outcomes Research and Policies

Meilin Liu
Yanqin Lu
Junfeng Li
Yongtao Zhang
Shanshan Zhang
Yisheng Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1278710

1,286 views

Original Research

Published on 10 Jun 2024

Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)

in Drugs Outcomes Research and Policies

Ruibo Li
Xingyue Yuan
Xi Chen
Yili Ou
Jin Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1358592

1,233 views

Original Research

Published on 10 Jun 2024

Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives

in Drugs Outcomes Research and Policies

Yena Gan
Fenghao Shi
He Zhu
Huangqianyu Li
Sheng Han
Duoduo Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1256992

795 views

Original Research

Published on 07 Jun 2024

Cost-effectiveness analysis of Anaprazole versus Ilaprazole for the treatment of duodenal ulcers in China

in Drugs Outcomes Research and Policies

Huitong Ni
Jiaqi Shi
Ming Hu
Naitong Zhou
Shu Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1407435

453 views

Original Research

Published on 05 Jun 2024

Evaluation of time to sputum smear conversion and its association with treatment outcomes among drug-resistant tuberculosis patients: a retrospective record-reviewing study

in Drugs Outcomes Research and Policies

Abdulaziz Ibrahim Alzarea
Amna Saifullah
Yusra Habib Khan
Adullah Salah Alanazi
Ahmed D. Alatawi
Majed Ahmed Algarni
Ziyad Saeed Almalki
Abdullah K. Alahmari
Hassan H. Alhassan
Tauqeer Hussain Mallhi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1370344

613 views

Correction

Published on 04 Jun 2024

Corrigendum: Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

in Drugs Outcomes Research and Policies

Truong Van Dat
Vo Linh Tu
Le Nguyen Anh Thu
Nguyen Nhat Anh Quang
Van Binh
Nguyen Thi Quynh Nga
Duong Hoang Loc
Tran Thi Hong Nguyen
Dao Ngoc Hien Tam
Hong-Han Huynh

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1426608

745 views

Original Research

Published on 04 Jun 2024

The impact of Chinese volume-based procurement on pharmaceutical market concentration

in Drugs Outcomes Research and Policies

Ying Yang
Yuxin Liu
Zongfu Mao
Jing Mao
Yalei Jin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1386533

1,477 views
1 citation

Original Research

Published on 03 Jun 2024

Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system

in Drugs Outcomes Research and Policies

Kaibin Niu
Maoxia Fan
Wulin Gao
Chen Chen
Guohua Dai

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1414268

2,276 views

Original Research

Published on 03 Jun 2024

Analysis and discussion on the pharmaceutical centralized procurement implementation — a case study of a large provincial hospital in China

in Drugs Outcomes Research and Policies

Jingjing Cao
Yuan Ren
Chenglong Zhao
Li Wang
Fengqin Fang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1379595

556 views

Review

Published on 30 May 2024

Osteogenic mechanism of chlorogenic acid and its application in clinical practice

in Drugs Outcomes Research and Policies

Jiayu Shen
Shichen Zhang
Jiayu Zhang
Xin Wei
Zilin Wang
Bing Han

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1396354

1,054 views
1 citation

Original Research

Published on 30 May 2024

Pharmaceutical interventions for drug-related problems in the neonatal intensive care unit: incidence, types, and acceptability

in Drugs Outcomes Research and Policies

Norhan Attia Ahmed
Ehab Ahmed Fouad
Osama M. El-Asheer
A. S. M. Ghanem

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1391657

1,297 views
1 citation

Systematic Review

Published on 28 May 2024

Effect of sacubitril–valsartan on left ventricular remodeling in patients with acute myocardial infarction after primary percutaneous coronary intervention: a systematic review and meta-analysis

in Drugs Outcomes Research and Policies

Yiheng Liu
Yue Sun
Weiran Dai

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1366035

1,131 views

Original Research

Published on 28 May 2024

Safety assessment of tranexamic acid: real-world adverse event analysis from the FAERS database

in Drugs Outcomes Research and Policies

Ningsheng Tian
Yuxin Sun
Yingying Liu
Jie Jin
Shuai Chen
Huawei Han
Ying Zhang
Zhiwei Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1388138

1,347 views
1 citation

Opinion

Published on 24 May 2024

Overlooking the obvious: the importance of communicating safety and risks of opioids-the Israeli context

in Drugs Outcomes Research and Policies

Maram Khazen
Shelly Kamin-Friedman

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1356968

384 views

Original Research

Published on 23 May 2024

Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy

in Drugs Outcomes Research and Policies

Tanja Elnaz Hassanzadeh
Carina Hohmann
Carsten Culmsee

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1194201

1,250 views

Navigation group

Articles

Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States

Orphan drug policy analysis in China

Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)

Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives

Cost-effectiveness analysis of Anaprazole versus Ilaprazole for the treatment of duodenal ulcers in China

Evaluation of time to sputum smear conversion and its association with treatment outcomes among drug-resistant tuberculosis patients: a retrospective record-reviewing study

Corrigendum: Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review

The impact of Chinese volume-based procurement on pharmaceutical market concentration

Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system

Analysis and discussion on the pharmaceutical centralized procurement implementation — a case study of a large provincial hospital in China

Osteogenic mechanism of chlorogenic acid and its application in clinical practice

Pharmaceutical interventions for drug-related problems in the neonatal intensive care unit: incidence, types, and acceptability

Effect of sacubitril–valsartan on left ventricular remodeling in patients with acute myocardial infarction after primary percutaneous coronary intervention: a systematic review and meta-analysis

Safety assessment of tranexamic acid: real-world adverse event analysis from the FAERS database

Overlooking the obvious: the importance of communicating safety and risks of opioids-the Israeli context

Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy